MediciNova, Inc. Form 10-Q Summary
Business Context and Reporting Period
MediciNova is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for serious diseases with unmet medical needs. Its primary programs are MN-166 (ibudilast) for progressive multiple sclerosis, ALS and substance dependence, and MN-001 (tipelukast) for NASH and IPF. The filing covers the three and six months ended June 30, 2016, and was filed July 26, 2016.
Key Financial Metrics
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $3.2 million | $6.6 million |
| Net loss | $3.2 million | $6.6 million |
| Net loss per share | $0.10 | $0.21 |
| Net cash used in operations | Not separately provided | $3.9 million |
- Research, development and patent expense was $1.0 million in the quarter and $2.0 million year to date.
- General and administrative expense was $2.2 million in the quarter and $4.6 million year to date.
- Cash and cash equivalents were $26.6 million at June 30, 2016, compared with $22.1 million at December 31, 2015.
- Working capital was $25.9 million at June 30, 2016.
- Total liabilities were $5.0 million, including $2.0 million of deferred tax liability and $1.7 million of deferred revenue. The filing reports no debt.
- Stockholders’ equity was $37.4 million, compared with $32.8 million at December 31, 2015.
- Cash flow from financing activities was $8.4 million, primarily from exercise of warrants and stock options.
- Accumulated deficit was $326.0 million at June 30, 2016.
Material Changes Versus Prior Comparable Period
- Second-quarter net loss increased to $3.2 million from $2.3 million; six-month net loss increased to $6.6 million from $4.5 million.
- Total operating expenses increased 41% in the quarter and 47% year to date, driven primarily by higher stock-based compensation and general and administrative costs.
- Research and development expense increased to $2.0 million year to date from $1.5 million, while general and administrative expense increased to $4.6 million from $3.0 million.
- Net cash used in operations improved to $3.9 million from $4.5 million year to date, primarily because of higher non-cash stock-based compensation and working-capital changes.
- Financing proceeds increased to $8.4 million from $1.4 million, principally due to the exercise of 2.1 million warrants and 159,285 stock options.
- Kissei converted all 220,000 Series B preferred shares into 2.2 million common shares on June 15, 2016.
- Common shares outstanding increased to 34.5 million at June 30, 2016 from approximately 30.0 million at December 31, 2015.
Guidance, Outlook, Risks and Unusual Items
- Management stated that available working capital was expected to fund operations at least through December 31, 2018, but cautioned that resources may not support all planned research and development programs.
- The company expects substantial net losses for the next several years and may need additional capital depending on development decisions.
- Management intends to advance MN-166 and MN-001 through a combination of investigator-sponsored trials, government or other grants, company funding and strategic alliances.
- The company expects to seek pharmaceutical partners after proof-of-concept Phase 2 trials to support later-stage development and commercialization.
- No revenue was recognized from the $2.5 million Kissei upfront payment during the quarter or year to date; $1.7 million remained recorded as long-term deferred revenue.
- The Zhejiang Sunmy China joint venture has not entered into the required sublicense for MN-221, and there is no assurance that development in China will proceed.
- Stock-based compensation was $1.3 million in the quarter and $2.8 million year to date, materially contributing to operating expenses.
- Outstanding securities included 5.1 million stock options and 1.1 million warrants, creating potential future dilution.
- Key risks include clinical-trial failure or delay, regulatory approval risk, dependence on MN-166 and MN-001, reliance on third parties, intellectual-property disputes, inability to raise capital or establish partnerships, and lack of future product revenue.
- Management reported no material legal proceedings, no material changes to previously disclosed risk factors, and effective disclosure controls as of June 30, 2016.
Investor Verification Checklist
- Verify the company’s cash runway against current clinical-trial plans, expected spending and potential capital requirements.
- Assess clinical progress, enrollment, funding and results for MN-166 and MN-001, particularly the SPRINT-MS and ALS programs.
- Review the status and economics of the proposed Zhejiang Sunmy sublicense and MN-221 development in China.
- Reconcile the increase in shares outstanding with warrant and option exercises and the preferred-stock conversion.
- Evaluate the impact of recurring stock-based compensation and potential dilution from outstanding options and warrants.
- Review the timing and collectability of the remaining Kissei deferred revenue.
- Confirm that no product candidate has received regulatory approval or generated product sales; the filing text does not provide a clear commercialization timeline.